Clinical trial · Interventional
BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma
Phase 1-2 Multi-Center Study of Intravenous BCX-1777 in Patients With Refractory Cutaneous T-Cell Lymphoma (CTCL)
NCT00061880CI-TRIAL-00010500completedPhase 1 / Phase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
RATIONALE: BCX-1777 may stop the growth of cancer cells by blocking the enzymes necessary for cancer cell growth. PURPOSE: Phase I/II trial to study the effectiveness BCX-1777 in treating patients who have refractory cutaneous T-cell lymphoma.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma | Lymphoma | ONTOLOGY_EXACT | 0.90 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| forodesine hydrochloride | Drug | — | UNRESOLVED |
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
DISEASE CHARACTERISTICS:
* Histologically confirmed cutaneous T-cell lymphoma (CTCL)
* Any stage except IA patch only
* Previously treated according to 1 of the following:
* Stage IA plaque, IB, or IIA:
* At least 4 prior conventional and/or experimental regimens (topical or systemic, including psoralen-ultraviolet light \[PUVA\] and systemic corticosteroids)
* Stage IIB, III, or IV:
* At least 1 prior systemic regimen (systemic corticosteroids and PUVA do not count as systemic regimens for this purpose) NOTE: Repeated use of the same regimen is considered one regimen
* Measurable disease
PATIENT CHARACTERISTICS:
Age
* 18 and over
Performance status
* ECOG 0-3
Life expectancy
* At least 3 months
Hematopoietic
* Granulocyte count at least 2,000/mm\^3
* Platelet count at least 75,000/mm\^3
* Hemoglobin at least 10.0 g/dL
Hepatic
* Bilirubin no greater than 1.5 times upper limit of normal (ULN) (unless due to Gilbert's syndrome)
* ALT no greater than 2 times ULN
* Alkaline phosphatase no greater than 2 times ULN
* No hepatitis B or C
Renal
* Creatinine clearance at least 45 mL/min
Other
* Not pregnant or nursing
* Negative pregnancy test
* Fertile patients must use effective contraception
* HIV negative
* Human T-cell leukemia virus type 1 (HTLV-1) negative
* No other malignancy within the past 5 years except basal cell or squamous cell skin cancer or carcinoma in situ of the cervix
* No other illness that would limit study participation
* No active serious infection not controlled by antibiotics
PRIOR CONCURRENT THERAPY:
Biologic therapy
* No concurrent anticancer antibody therapy
* No concurrent anticancer immunotherapy
* No concurrent anticancer gene therapy
* No concurrent anticancer vaccine therapy
* No concurrent anticancer angiogenesis inhibitors
* No concurrent sargramostim (GM-CSF)
* No concurrent filgrastim (G-CSF) during course 1 of therapy
Chemotherapy
* More than 21 days since prior chemotherapy unless fully recovered
* No concurrent anticancer chemotherapy
Endocrine therapy
* See Disease Characteristics
* More than 2 weeks since prior topical corticosteroids
* No concurrent anticancer hormonal therapy
Radiotherapy
* More than 2 weeks since prior radiotherapy
* No concurrent radiotherapy
Surgery
* Not specified
Other
* More than 2 weeks since prior antineoplastic therapy
* More than 21 days since prior investigational agents unless fully recovered
* No concurrent citrate-blood products within 30 minutes before or after study treatment
* No concurrent anticancer matrix metalloprotease inhibitors
* No other concurrent anti-CTCL therapy
* No concurrent use of tanning beds
* No other concurrent investigational agentsReferences
Publications (0)
Data not yet available
No reference posted for this study.